Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

Measurable residual disease testing for personalized treatment of acute myeloid leukemia

Ehinger, Mats LU and Pettersson, Louise LU orcid (2019) In APMIS 127(5). p.337-351
Abstract

This review summarizes – with the practicing hematologist in mind – the methods used to determine measurable residual disease (MRD) in everyday practice with some future perspectives, and the current knowledge about the prognostic impact of MRD on outcome in acute myeloid leukemia (AML), excluding acute promyelocytic leukemia. Possible implications for choice of MRD method, timing of MRD monitoring, and guidance of therapy are discussed in general and in some detail for certain types of leukemia with specific molecular markers to monitor, including core binding factor (CBF)-leukemias and NPM1-mutated leukemias.

Please use this url to cite or link to this publication:
author
and
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
Acute myeloid leukemia, CBF leukemia, CBFB-MYH11, flow cytometry, inv(16), measurable residual disease, multicolor flow cytometry, NPM1, personalized treatment, RUNX1-RUNX1T1, t(16;16), t(8;21)
in
APMIS
volume
127
issue
5
pages
337 - 351
publisher
John Wiley & Sons Inc.
external identifiers
  • scopus:85063576379
  • pmid:30919505
ISSN
0903-4641
DOI
10.1111/apm.12926
language
English
LU publication?
yes
id
5f0bb456-67b6-4f17-9add-f48d4d6b1831
date added to LUP
2019-04-08 13:17:20
date last changed
2024-06-11 08:03:44
@article{5f0bb456-67b6-4f17-9add-f48d4d6b1831,
  abstract     = {{<p>This review summarizes – with the practicing hematologist in mind – the methods used to determine measurable residual disease (MRD) in everyday practice with some future perspectives, and the current knowledge about the prognostic impact of MRD on outcome in acute myeloid leukemia (AML), excluding acute promyelocytic leukemia. Possible implications for choice of MRD method, timing of MRD monitoring, and guidance of therapy are discussed in general and in some detail for certain types of leukemia with specific molecular markers to monitor, including core binding factor (CBF)-leukemias and NPM1-mutated leukemias.</p>}},
  author       = {{Ehinger, Mats and Pettersson, Louise}},
  issn         = {{0903-4641}},
  keywords     = {{Acute myeloid leukemia; CBF leukemia; CBFB-MYH11; flow cytometry; inv(16); measurable residual disease; multicolor flow cytometry; NPM1; personalized treatment; RUNX1-RUNX1T1; t(16;16); t(8;21)}},
  language     = {{eng}},
  month        = {{03}},
  number       = {{5}},
  pages        = {{337--351}},
  publisher    = {{John Wiley & Sons Inc.}},
  series       = {{APMIS}},
  title        = {{Measurable residual disease testing for personalized treatment of acute myeloid leukemia}},
  url          = {{http://dx.doi.org/10.1111/apm.12926}},
  doi          = {{10.1111/apm.12926}},
  volume       = {{127}},
  year         = {{2019}},
}